StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
BROACH.BO$15.00+0.00%
Fair $15.00+0.0%

BROACH.BO

BROACH.BO

Healthcare / Medical Care FacilitiesBSE

$15.00

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $15.00Fund rank 21/100 · Data gapFallback financials|
SA 27/D
F-Score: 4/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 18%

FCF escenarios

weak_data · normalized FCF $-19.8M · quality 39.7/100

Data gap 21/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 13/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

27/100

D

Piotroski

4/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

20/100

SEC 0%

Latest source: yahooPeriods: 5Warnings: 1yahoo: 5
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is 0.9%, below the 5% threshold
Thesis & Journal · BROACH.BOLocal privado en este navegador · BROACH.BO
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$91M

P/E

107.1x

↑

EV/EBITDA

16.1x

↑

ROE

0.9%

↑

Gross Margin

54.0%

↑

Debt/Equity

N/A

•
No hay histórico de precio usable para pintar el gráfico TradingView.

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2026 · 4 años de histórico normalizado

Revenue CAGR

+15.3%

FCF CAGR

—

FCF margin

-33.0%

FCF / Net income

-22.79x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $59.9M · net income $868000.0 · FCF $-19.8M

2022-FY → 2026-FY

Gross margin

54.0%+5.8% pts

Operating margin

3.5%-24.4% pts

Net margin

1.4%-12.1% pts

FCF margin

-33.0%+19.0% pts
MetricTTM
2026
2025
2024
2023
2022
Income Statement
Revenue$59.9M$59.9M$31.8M$26.1M$18.2M$33.9M
Net Income$868000.00$868000.00$5.4M$7.0M$1.4M$4.6M
EBITDA$5.5M$5.5M$8.7M$10.3M$8.4M$10.3M
EPS——0.981.150.230.76
Gross Margin54.0%54.0%54.4%59.7%54.0%48.2%
Operating Margin3.5%3.5%21.9%36.5%19.7%27.8%
Net Margin1.4%1.4%16.9%26.8%7.6%13.5%
Balance Sheet
Debt/Equity——0.11—2.741.13
Current Ratio3.093.09————
Cash Flow
Free Cash Flow$-19.8M$-19.8M$-10.2M$-47.0M$-28.3M$-17.6M
Returns
ROE0.9%0.9%5.7%12.8%6.4%20.4%
Valuation
P/E107.14107.1419.64———
EV/EBITDA16.0516.0513.03———
P/B0.960.961.12———
Growth & Yield
Revenue Growth88.5%88.5%22.0%43.5%——
EPS Growth——-14.7%403.7%——

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · available periodreconcilia total n/d
Return attribution requires positive start and end prices.

Unavailable: positive start/end prices are required.